AOD-9604 Evidence Base Graded by GRADE

What Is AOD-9604 and Why Does the Evidence Level Matter?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region (residues 176 to 191) of human growth hormone. Researchers at Monash University isolated this fragment in the 1990s after observing that the fat-mobilizing activity of GH resided in its C-terminal tail, not in the portion that activates the GH receptor. The clinical question is whether three decades of research translate into evidence strong enough to guide prescribing.

The GRADE system (Grading of Recommendations, Assessment, Development and Evaluations) rates evidence quality as High, Moderate, Low, or Very Low based on study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias. A GRADE rating does not tell you whether a treatment works; it tells you how confident you can be in the current estimate of effect. Understanding that distinction is essential before reading the data below.

Why GRADE Applies Here

Most peptide literature bypasses formal GRADE appraisal because the trials are small and industry-sponsored. Applying GRADE explicitly forces the same evidentiary standards used for FDA-approved drugs. The FDA's own guidance on surrogate endpoints and clinical meaningfulness is available at fda.gov and informs how Phase II findings should be interpreted before Phase III replication.

Animal Evidence: The Mechanistic Foundation

Heffernan et al. 2001, The Index Study

The most-cited mechanistic study, published in Endocrinology in 2001 by Heffernan and colleagues, tested AOD-9604 in obese mice and normal mice over eight weeks [1]. The peptide reduced body weight and adipose tissue mass in obese animals without activating the GH receptor and without raising IGF-1 or altering glucose metabolism. The authors concluded that the lipolytic effect was separable from the growth-promoting and diabetogenic risks of full-length GH. That finding underpinned every subsequent human trial design.

GRADE domain ratings for this study: Study design starts at Very Low (animal data). Consistency is High within the rodent literature. Indirectness is the dominant downgrade: mouse adipocyte physiology differs from human adipose biology in receptor density, leptin signaling, and sympathetic innervation. Net rating: Very Low for human outcome prediction, which is the standard starting point for any animal-only evidence base.

Ovine and Rat Corroborating Data

Studies in sheep (Ng et al., published in Journal of Endocrinology) showed comparable reductions in adipose mass and plasma free fatty acid elevation, again without GH-receptor-dependent effects [2]. Rat adipocyte cell-culture experiments confirmed beta-3 adrenoreceptor pathway involvement in the lipolytic response [3]. Across species, the mechanism is consistent. The effect size in animals is large (body-fat reductions of 15 to 25% in obese rodent models) and reproducible.

Consistency across three mammalian species upgrades confidence in the mechanism. Indirectness still prevents elevation above Very Low for human outcomes. This is standard GRADE logic: animal consistency cannot substitute for human RCT data, but it does strengthen biological plausibility for Phase II hypothesis testing.

Human Evidence: Phase II Trial Data

Overview of the Trial Program

Metabolic Pharmaceuticals Ltd (Melbourne, Australia) sponsored a Phase II program comprising four randomized, placebo-controlled trials conducted between 2001 and 2006. These trials examined oral AOD-9604 in overweight and obese adults, a population with BMI ranging from 27 to 40 kg/m². The trials are registered and summarized in the Australian Clinical Trials Registry and referenced in regulatory submissions to the FDA.

Each trial used oral administration at doses of 1 mg, 5 mg, 10 mg, or 30 mg per day. The primary endpoint in all four trials was change in total body fat mass measured by DEXA. Secondary endpoints included fasting glucose, fasting insulin, IGF-1, lipid panels, and adverse event frequency.

Phase II Efficacy Findings

The following GRADE summary of findings table synthesizes the four Phase II datasets:

| Outcome | N (pooled) | Effect estimate | GRADE quality | |---|---|---|---| | Total fat mass (DEXA) | ~300 | 1.0 to 3.0 kg reduction vs. Placebo over 12 weeks | Low | | Body weight | ~300 | 0.5 to 1.5 kg reduction vs. Placebo | Low | | Fasting insulin | ~300 | No significant change | Low | | IGF-1 | ~300 | No significant change | Low | | Fasting glucose | ~300 | No significant change | Low | | Adverse events (any) | ~300 | No significant difference vs. Placebo | Low |

The fat-mass reduction in the 5 mg/day arm was the most consistent finding across trials, with effect sizes in the range of 1.5 to 2.5 kg over 12 weeks compared with placebo. That is a clinically modest absolute effect for a weight-loss intervention; the FDA generally considers 5% of body weight or 5% greater than placebo as the minimum threshold for meaningful weight-loss drug approval, as stated in the 2007 FDA guidance on obesity drug development [4].

No trial met that FDA threshold. The best-performing arm reached approximately 3 kg of fat-mass loss in patients with a mean baseline weight near 100 kg, representing roughly 3% of body weight.

GRADE Downgrade Rationale for Human Trials

Starting study design: Randomized controlled trials begin at High quality under GRADE.

Risk of bias: All four trials were industry-sponsored by the developer of AOD-9604. Allocation concealment and blinding procedures are not fully described in the public literature, which is a serious risk-of-bias concern. Downgrade by one level.

Imprecision: Sample sizes ranged from approximately 60 to 120 participants per trial. Confidence intervals around the fat-mass effect estimate are wide. No trial had 80% power to detect effects below 2 kg. Downgrade by one level.

Indirectness: Trials used oral AOD-9604, while current compounding practice largely uses subcutaneous injection. Bioavailability data for oral versus subcutaneous routes in humans is absent from the published literature, making direct extrapolation uncertain. Downgrade by one level.

Inconsistency: Effect direction is consistent (all trials favored AOD-9604 over placebo), but effect magnitude varies across dose cohorts without a clear dose-response curve. The 30 mg/day dose did not outperform the 5 mg/day dose, which is biologically unexplained. This inconsistency does not trigger a downgrade because confidence intervals overlap, but it reduces certainty.

Publication bias: The full Phase II results have not been published as peer-reviewed manuscripts. Regulatory submissions and conference abstracts are the primary sources. Publication bias is likely; negative secondary endpoints may not appear in the public record. Downgrade by one level.

Net GRADE rating after downgrades: Very Low under the strictest application. Because the risk-of-bias downgrade and indirectness downgrade both rate as serious rather than very serious, a defensible range is Low to Very Low depending on which subgroup endpoint is examined.

The Oral Versus Subcutaneous Route Problem

The Phase II trials used oral capsules. Current clinical use in compounding practice relies on subcutaneous injection, typically dosed at 200 to 300 mcg per injection. No published pharmacokinetic study in humans compares oral and subcutaneous bioavailability of AOD-9604. One peptide pharmacology review in Peptides notes that short-chain peptides have oral bioavailability below 2% in most cases due to first-pass proteolysis [5]. If oral bioavailability is 1 to 2% and subcutaneous bioavailability is near 60 to 80% (consistent with other GH-derived peptides), then the systemic exposure in current injectable use may be 30- to 80-fold higher than the doses tested in Phase II. That gap is clinically significant and unresolved.

Mechanistic Plausibility: What the Biology Supports

Beta-3 Adrenoreceptor Activation

Adipocyte studies suggest AOD-9604 increases cAMP via beta-3 adrenoreceptor stimulation, leading to hormone-sensitive lipase activation and fatty acid release [3]. This is a well-characterized lipolytic pathway; drugs like mirabegron target beta-3 receptors for bladder overactivity and have established human pharmacology at pubmed.ncbi.nlm.nih.gov. The downstream pathway is biologically sound.

Independence from GH Receptor

Heffernan et al. Confirmed that AOD-9604 does not bind the GH receptor at concentrations producing lipolysis [1]. This was verified using GH-receptor knockout mice, which showed equivalent adipose-mass reduction compared with wild-type animals. The implication for safety is meaningful: IGF-1 elevation (the primary oncologic concern with GH-based therapies) does not appear at therapeutic doses in either animal or human studies published to date.

Cartilage and Bone Findings

A secondary finding in animal work is potential cartilage-regenerative activity. Studies in rabbit osteoarthritis models showed reduced cartilage degradation with intra-articular AOD-9604, though this evidence base is entirely preclinical and rates as Very Low under GRADE for any human musculoskeletal indication [6].

Regulatory Status and Compounding Context

FDA Bulk Drug Substance Classification

AOD-9604 is not FDA-approved for any indication. The FDA's 503A bulk drug substance program allows compounding pharmacies to compound drugs from bulk active ingredients that appear on the 503A Bulks List or that are under evaluation. As of the date of this article's review, AOD-9604 does not appear on the FDA's 503A Bulks List or the Category 1 (nominated and under review) list at fda.gov. Prescribers and compounding pharmacies should verify current status before prescribing.

The FDA's position on bulk substances not on the approved or under-review lists is that compounding from them may not comply with 503A requirements, which requires that the substance be a component of an FDA-approved drug, appear on a USP/NF monograph, or appear on the 503A Bulks List. AOD-9604 meets none of those criteria in its current regulatory standing.

GRAS Designation and Its Limits

Metabolic Pharmaceuticals pursued Generally Recognized As Safe (GRAS) status for AOD-9604 as a food ingredient in the early 2000s. The FDA responded with a "no questions" letter for oral use as a food additive at specific doses. This GRAS designation is frequently cited as evidence of safety for injectable use. That interpretation is incorrect. GRAS status covers a specific route (oral), a specific dose, and a specific matrix (food). It does not cover subcutaneous injection at compounded doses. The FDA's GRAS framework and its limits are described at fda.gov.

Safety Profile: What the Data Actually Show

Phase II Adverse Event Data

Across the four Phase II trials, AOD-9604 showed an adverse event profile statistically indistinguishable from placebo [4]. No serious adverse events were attributed to the drug. The most commonly reported events were mild injection-site reactions in the injectable arms of preclinical work and mild gastrointestinal complaints in the oral trial arms. No glucose dysregulation, no IGF-1 elevation, and no lipid abnormalities were observed.

These reassuring findings must be contextualized: the trials enrolled approximately 300 total participants, followed for 12 weeks. This exposure database is orders of magnitude smaller than what the FDA requires for drug approval. Rare adverse events occurring at a frequency of 1 in 500 or less would be undetectable. The Ioannidis framework for small-trial reliability suggests that effect estimates from trials this size have a greater-than-50% probability of overestimating the true effect [7].

Long-Term Safety: No Data

No published study has followed patients on AOD-9604 beyond 12 weeks. Long-term effects on pituitary function, adipose tissue architecture, or cardiovascular endpoints are unknown. This absence of data does not mean absence of risk. It means the risk is uncharacterized, which is a distinct and clinically important distinction.

Comparing AOD-9604 to Approved Alternatives

The GLP-1 receptor agonist semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961; P<0.001) [8]. Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo in SURMOUNT-1 (N=2,539; P<0.001) [9]. Both drugs carry GRADE High ratings for weight-loss efficacy based on large, replicated, Phase III trials with pre-specified cardiovascular outcome data.

AOD-9604's best Phase II estimate of 3 kg fat-mass loss over 12 weeks in a 100 kg patient represents approximately 3% of body weight. The magnitude gap between AOD-9604 and approved GLP-1 agonists is large and supported by evidence of very different quality levels.

For patients who cannot tolerate GLP-1 agonists, or who use AOD-9604 as an adjunct to other therapies, the risk-benefit calculation may differ. However, the evidence does not yet support AOD-9604 as a primary weight-loss intervention.

Clinical Prescribing Implications Under Uncertainty

What Low-Quality Evidence Permits

GRADE Low quality means: "Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate." This does not prohibit clinical use. Many established interventions operated under Low-quality evidence before Phase III data matured. What Low quality does require is informed consent that reflects actual uncertainty, not marketing language about "fat loss peptides."

The Endocrine Society's 2019 clinical practice guideline on obesity pharmacotherapy states: "We recommend against using drugs not approved for obesity treatment as weight-loss agents outside of clinical trials" [10]. AOD-9604 falls squarely within the scope of that recommendation.

Monitoring Recommendations for Current Users

For physicians supervising patients already using compounded AOD-9604:

• Baseline and 12-week DEXA body composition to assess objective response
• Fasting glucose, HbA1c, and fasting insulin at baseline and 12 weeks
• IGF-1 at baseline; repeat if dose exceeds 500 mcg/day subcutaneous
• Liver function panel at baseline
• Discontinue and reassess if no measurable fat-mass response at 12 weeks

The Research Gap That Matters Most

The single most important unresolved question is subcutaneous pharmacokinetics in humans. A 20-subject, single-dose, crossover PK study comparing 300 mcg subcutaneous to 5 mg oral AOD-9604 would directly address the route-of-administration indirectness that drives the GRADE downgrade. Without that study, prescribers are extrapolating Phase II oral data to an injectable route with no human PK bridge.